Mike Kijewski, CEO, discusses MedCrypt, the company he launched in 2016 after seeing a particular 2012 episode of Homeland, that provides proactive cybersecurity solutions to medical device vendors.
Dr. Alyssa Dweck discusses this condition that many women are uncomfortable talking to their healthcare providers about. Hypoactive sexual desire disorder or HSDD is biological and not a result of issues or unhappiness. It can be handled with proper care and treatment. Learn more at Vyleesi. PRODUCT IS ONLY APPROVED FOR USE IN THE U.S.
Mike Davis, Head of the U.S. Neurology Patient Value Unit at UCB, a global pharmaceutical company, discusses the collaboration with the University of Washington’s School of Pharmacy to improve access to care for people living with epilepsy. This interdisciplinary project will explore ways in which community pharmacists can better support people living with this neurological disorder.
Dr. Jonathan Steinfeld, global clinical lead for the GSK mepolizumab pediatric asthma indication discusses the recent FDA approval of GSK’s Nucala (mepolizumab) the only biologic for use in children as young as 6 years old that have severe eosinophilic asthma.
Tony Abate, Vice President & Chief Technical Officer at AtmosAir in Fairfield, CT, discusses the benefits of high-tech Indoor Air Quality (IAQ) devices in hospitals and medical offices. He says they help to eliminate dust particles, mold, odors, mildew and bacteria that create an unhealthy environment in a hospital and cause illness and infections.
Over 200,000 cosmetic procedures were performed on teens last year. Board Certified Facial Plastic Surgeon, Dr. Demetri Arnaoutakis discusses why we are seeing an increase in teens, ages 13 to 19, getting plastic surgery and the dangers associated with it.
New CEO of Squarex, Jack V. Talley discusses the positive results of the phase 2 study on their new investigational drug candidate SQX770, a topical immunomodulator treatment to extend the time between herpes labialis (recurrent cold sores) outbreaks caused by Herpes Simplex Virus 1 or Herpes Simplex Virus 2. Squarex is a clinical-stage pharmaceutical company.
Dr. Doug Manion, CEO of Kleo Pharmaceuticals, discusses his personal journey from working as an engineer in Africa to going to med school and then moving into drug development.
Kleo Pharmaceuticals is a unique immuno-oncology company poised to solve some of the problems dominating the headlines for the biopharmaceutical industry. CEO Dr. Doug Manion discusses the development of next-generation bispecific compounds designed to emulate or enhance the activity of biologics, which directly engage patients’ immune systems to target and destroy cancer cells. Human studies are anticipated in 2020.